Patent expirations won't hold back success of some drug firms

11/18/2003 | Bloomberg Businessweek

Although many drug firms are facing patent expirations next year, investors are bullish on several companies. For example, Pfizer is favored among investors based on anticipated 2004 sales of its recently approved drug for congestive heart failure. Abbott recently launched Humira, a rheumatoid arthritis drug that could be a hit, while Wyeth's lack of patent expirations could outweigh its weak pipeline.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC